Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 2669 of 3330
Next
>>
>
66701 to 66725 of 83232 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Small Molecule	Perturbagen Target	Perturbagen Class	Perturbagen Concentration	Perturbagen Conc Unit	Biological Replicate ID	Relative Cell Count	Normalized Growth Rate Inhibition Value	Nominal Division Rate
HCC2185	TNBC	Luminal	Sirolimus	MTOR	MTOR	0.00213	uM	7845.068	0.8188	0.1898	0.3849
HCC2185	TNBC	Luminal	Sirolimus	MTOR	MTOR	0.0107	uM	7845.068	0.7079	-0.1848	0.3849
HCC2185	TNBC	Luminal	Sirolimus	MTOR	MTOR	0.0533	uM	7845.068	0.6128	-0.4396	0.3849
HCC2185	TNBC	Luminal	Sirolimus	MTOR	MTOR	0.267	uM	7845.068	0.6633	-0.3115	0.3849
HCC2185	TNBC	Luminal	Sirolimus	MTOR	MTOR	1.33	uM	7845.068	0.6249	-0.4104	0.3849
HCC2185	TNBC	Luminal	Sirolimus	MTOR	MTOR	6.67	uM	7845.068	0.7101	-0.1782	0.3849
HCC2185	TNBC	Luminal	Sirolimus	MTOR	MTOR	33.3	uM	7845.068	0.5974	-0.4753	0.3849
HCC2185	TNBC	Luminal	Sirolimus	MTOR	MTOR	167	uM	7845.068	0.5655	-0.5451	0.3849
HCC2185	TNBC	Luminal	Sirolimus	MTOR	MTOR	0.000427	uM	7846.068	0.9513	0.8112	0.5039
HCC2185	TNBC	Luminal	Sirolimus	MTOR	MTOR	0.00213	uM	7846.068	0.8065	0.3054	0.5039
HCC2185	TNBC	Luminal	Sirolimus	MTOR	MTOR	0.0107	uM	7846.068	0.7021	-0.0087	0.5039
HCC2185	TNBC	Luminal	Sirolimus	MTOR	MTOR	0.0533	uM	7846.068	0.5901	-0.2977	0.5039
HCC2185	TNBC	Luminal	Sirolimus	MTOR	MTOR	0.267	uM	7846.068	0.6093	-0.2517	0.5039
HCC2185	TNBC	Luminal	Sirolimus	MTOR	MTOR	1.33	uM	7846.068	0.6117	-0.2458	0.5039
HCC2185	TNBC	Luminal	Sirolimus	MTOR	MTOR	6.67	uM	7846.068	0.6305	-0.1992	0.5039
HCC2185	TNBC	Luminal	Sirolimus	MTOR	MTOR	33.3	uM	7846.068	0.6035	-0.2659	0.5039
HCC2185	TNBC	Luminal	Sirolimus	MTOR	MTOR	167	uM	7846.068	0.4777	-0.5384	0.5039
HCC3153	TNBC	Basal A	Sirolimus	MTOR	MTOR	0.0000853	uM	7467.069	1.0034	1.0054	1.2461
HCC3153	TNBC	Basal A	Sirolimus	MTOR	MTOR	0.000427	uM	7467.069	0.9516	0.9220	1.2461
HCC3153	TNBC	Basal A	Sirolimus	MTOR	MTOR	0.00213	uM	7467.069	1.0141	1.0226	1.2461
HCC3153	TNBC	Basal A	Sirolimus	MTOR	MTOR	0.0107	uM	7467.069	0.8809	0.8065	1.2461
HCC3153	TNBC	Basal A	Sirolimus	MTOR	MTOR	0.0533	uM	7467.069	0.8433	0.7443	1.2461
HCC3153	TNBC	Basal A	Sirolimus	MTOR	MTOR	0.267	uM	7467.069	0.8451	0.7474	1.2461
HCC3153	TNBC	Basal A	Sirolimus	MTOR	MTOR	1.33	uM	7467.069	0.8353	0.7310	1.2461
HCC3153	TNBC	Basal A	Sirolimus	MTOR	MTOR	6.67	uM	7467.069	0.7802	0.6387	1.2461

|<
<<
Previous
Page 2669 of 3330
Next
>>
>
66701 to 66725 of 83232 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)